GLP-1 Side Effects: A Complete Overview of Nausea, Constipation, Sulfur Burps, and Gallbladder Risk

What Are the Most Common GLP-1 Side Effects?

Gastrointestinal symptoms dominate the side-effect profile of every approved GLP-1 receptor agonist. In STEP-1 (Wilding et al., NEJM 2021, N=1,961), semaglutide 2.4 mg weekly produced nausea in 44.2% of participants, diarrhea in 31.5%, vomiting in 24.8%, and constipation in 23.4%, all compared to a placebo group where combined GI events occurred in roughly 48% of patients [1]. The vast majority of these events were mild to moderate in severity and did not require treatment discontinuation.

Tirzepatide shows a similar pattern. SURMOUNT-1 (Jastreboff et al., NEJM 2022, N=2,539) reported nausea in 39% of patients on the 15 mg dose, diarrhea in 23%, constipation in 17%, and vomiting in 13% [2]. Roughly 80% of tirzepatide 15 mg patients reported at least one GI event over the trial period, compared with 74% for semaglutide 2.4 mg in STEP-1 [1][2].

Both drugs carry identical FDA boxed warnings for thyroid C-cell tumors based on rodent carcinogenicity data, though no human cases attributable to these agents have been confirmed [3][4]. Less common serious adverse events include acute pancreatitis, gallbladder disease, and acute kidney injury secondary to dehydration during severe vomiting episodes.

Side effects are most concentrated during the titration phase. The Wegovy prescribing label specifies a 16-to-20-week titration schedule from 0.25 mg to 2.4 mg weekly precisely to reduce GI exposure at each new dose level [3]. The Zepbound label uses a comparable 20-week step-up from 2.5 mg to 15 mg [4].

Discontinuation due to adverse events reached 7.0% on semaglutide 2.4 mg versus 3.1% on placebo in STEP-1 [1], and approximately 4 to 7% across tirzepatide dose arms in SURMOUNT-1 [2]. Those figures are lower than many patients expect, which means the majority of people who experience early nausea do continue and adapt.

How to Manage Nausea on GLP-1 Medications

Nausea on GLP-1 drugs is a direct pharmacological effect of slowed gastric emptying and central GLP-1 receptor activation in the brainstem. It is not an allergic reaction, and it typically improves within 4 to 8 weeks at any given dose level [1][3].

The four strategies with the most clinical support:

Slow the titration. The Wegovy label's approved ramp-up spans 16 weeks minimum [3]. Patients who advance doses faster than prescribed have higher nausea rates. A 2022 analysis of STEP-3 (N=611, JAMA) confirmed that patients in the intensive behavioral therapy arm who adhered strictly to titration had lower dropout rates than those who deviated [5].

Eat smaller, lower-fat meals. Fat delays gastric emptying independently of drug effects, compounding the GLP-1-induced slowing. Clinical dietitian guidance within the STEP-3 protocol specified meals under 500 kcal at injection time and avoidance of high-fat foods during the first hour post-injection [5].

Time the injection strategically. Injecting at bedtime means peak plasma concentration and the strongest gastric-emptying inhibition occur while the patient is asleep, when nausea is less noticeable. The Wegovy label does not mandate a specific injection time, leaving this a patient-preference decision [3].

Consider short-term antiemetics. Ondansetron 4 mg or promethazine 12.5 mg are sometimes prescribed for the first 2 to 4 weeks at a new dose. No large RCT has evaluated antiemetics specifically in GLP-1 patients, but clinical practice guidelines from the American Association of Clinical Endocrinologists acknowledge supportive pharmacotherapy as an acceptable management option [6].

In STEP-8 (Rubino et al., JAMA 2022, N=338), once-weekly semaglutide 2.4 mg produced significantly lower nausea rates than once-daily liraglutide 3.0 mg (29% vs. 37%), suggesting that dosing frequency itself modifies GI tolerability [7]. Patients who do not tolerate semaglutide may therefore respond differently to tirzepatide, and vice versa.

GLP-1 and Constipation: Causes and Solutions

Constipation affects roughly 1 in 4 patients on semaglutide or tirzepatide and tends to persist longer than nausea. In STEP-1, constipation was reported in 23.4% of the semaglutide arm versus 11.5% on placebo [1]. SURMOUNT-1 recorded 17% constipation on tirzepatide 15 mg [2]. Unlike nausea, constipation does not reliably resolve after titration ends; some patients experience it throughout treatment.

The mechanism is straightforward. GLP-1 receptors are present along the enteric nervous system. Agonist binding slows colonic transit time, the same mechanism that slows gastric emptying [8]. Reduced caloric intake on the drug also means less dietary bulk reaching the colon.

Practical management follows a stepwise approach:

1. Increase daily water intake to at least 2 liters. Dehydration worsens stool hardness and is common in patients experiencing concurrent nausea-related reduced oral intake.
2. Add soluble fiber (psyllium husk 5 to 10 g/day). A 2020 Cochrane review of fiber supplementation for chronic constipation (35 trials, N=3,752) found psyllium superior to placebo for stool frequency and consistency [9].
3. Use osmotic laxatives as needed. Polyethylene glycol (MiraLAX 17 g/day) is first-line per American Gastroenterological Association guidance because it is well tolerated and non-habit-forming [10].
4. Reserve stimulant laxatives (bisacodyl, senna) for refractory cases. They are effective but can cause cramping that mimics drug-related abdominal discomfort, complicating the clinical picture.

Patients should contact their prescriber if constipation is accompanied by abdominal distension, vomiting, or the complete absence of bowel movements for more than 5 days. These signs may indicate gastroparesis or, rarely, ileus, both listed as post-marketing adverse events in the Wegovy and Zepbound labels [3][4].

What Causes Sulfur Burps on GLP-1 Drugs?

Sulfur burps are one of the more distressing and least discussed GLP-1 side effects. They occur in a meaningful subset of patients, though trial-level data on frequency are sparse because sulfur burping was not a pre-specified adverse event endpoint in STEP or SURMOUNT trials.

The mechanism connects directly to slowed gastric emptying. When food stagnates in the stomach for longer than normal, sulfur-containing amino acids (methionine, cysteine) undergo bacterial fermentation, releasing hydrogen sulfide gas [8][11]. That gas exits via belching. The smell, often described as rotten eggs, is hydrogen sulfide.

Patients most prone to sulfur burps tend to eat high-protein meals (protein is sulfur-rich) or consume foods high in sulfur compounds: eggs, red meat, cruciferous vegetables, onions, and garlic. Cutting these foods during the first 12 weeks of treatment reduces the substrate available for fermentation.

Three additional strategies:

Eat slowly and stop before fullness. Overfilling a stomach that is already slow to empty extends fermentation time.

Avoid carbonated beverages. Carbonation adds gas volume on top of bacterial gas production.

Try simethicone 125 mg after meals. Simethicone is a defoaming agent that reduces gas bubble size. Evidence in this specific population is anecdotal, but its safety profile is well established and it carries no systemic absorption [12].

If sulfur burps are accompanied by severe nausea, vomiting, and upper-right-quadrant pain, the combination may signal gallbladder involvement rather than simple gastric slowing, as covered in the next section.

Gallbladder Risk on GLP-1 Medications

Gallbladder disease is the most clinically significant non-GI adverse effect of GLP-1 receptor agonists, and it is often underemphasized in patient counseling. In STEP-1, cholelithiasis (gallstones) or cholecystitis occurred in 2.6% of semaglutide patients versus 1.2% on placebo, a statistically significant difference (P<0.001) [1]. The Wegovy FDA label includes a specific warning for gallbladder disease and recommends clinical evaluation if patients develop upper-abdominal pain, jaundice, or fever [3].

Tirzepatide carries the same signal. The Zepbound label lists cholelithiasis as a reported adverse event, with gallbladder disease occurring more frequently in treated patients than in placebo [4]. SURMOUNT-1 data showed cholelithiasis in approximately 1% of tirzepatide patients across dose arms, though the trial was not designed to determine incidence with precision [2].

Two mechanisms drive this risk. First, rapid weight loss of any cause (including dietary restriction alone) increases bile cholesterol saturation and promotes gallstone formation. GLP-1 drugs accelerate weight loss substantially. In STEP-5 (Garvey et al., Nature Medicine 2022, N=304), patients maintained 15.2% mean weight loss at 104 weeks on semaglutide 2.4 mg [13], a degree of sustained loss that historically correlates with elevated gallbladder disease rates. Second, GLP-1 receptor agonists reduce gallbladder motility directly, impairing bile ejection fraction and allowing bile to stagnate [14].

Risk factors for GLP-1-associated gallbladder disease include:

• Female sex
• Age over 40
• Prior history of gallstones
• Rapid early weight loss (greater than 1.5 kg per week in the first month)
• Use of concurrent estrogen therapy

The American Association of Clinical Endocrinologists 2016 obesity management guidelines recommend baseline abdominal history-taking before initiating weight-loss pharmacotherapy and prompt imaging workup for any right-upper-quadrant pain during treatment [6].

Patients who develop acute cholecystitis require surgical consultation. Cholecystectomy, not drug discontinuation alone, is the definitive treatment. Stopping the GLP-1 agonist does not resolve an already-inflamed gallbladder.

Serious but Rare Side Effects: Pancreatitis, Kidney Injury, and the Thyroid Warning

Acute Pancreatitis

Acute pancreatitis is a labeled risk for all GLP-1 receptor agonists. The absolute incidence in clinical trials is low, under 0.5% in both STEP and SURMOUNT programs [1][2], but the condition is potentially life-threatening and mandates immediate emergency evaluation. Symptoms include severe, persistent mid-epigastric pain radiating to the back, nausea, and vomiting that does not subside. The Wegovy and Zepbound labels state that the drug should be discontinued if pancreatitis is confirmed and not restarted [3][4].

A 2014 meta-analysis by Monami et al. (published in Diabetes, Obesity and Metabolism) covering 60 RCTs of GLP-1 agents found no statistically significant increase in pancreatitis risk versus comparators, though the confidence intervals were wide [15]. The FDA has not issued a definitive causality determination, but the boxed and warning sections of current labels still flag it based on post-marketing case reports.

Acute Kidney Injury

Acute kidney injury in GLP-1 users is almost always secondary to dehydration from severe vomiting or diarrhea, not a direct nephrotoxic drug effect. The SELECT trial (Lincoff et al., NEJM 2023, N=17,604) actually showed a 22% relative reduction in kidney-disease progression with semaglutide 2.4 mg versus placebo in patients with existing cardiovascular disease [16]. Maintaining adequate hydration during any GI flare is the core preventive measure. Patients on ACE inhibitors, ARBs, or NSAIDs should be specifically cautioned, as those drugs amplify dehydration-related nephrotoxicity risk.

Thyroid C-Cell Tumors

Both the Wegovy and Zepbound labels carry a boxed warning for thyroid C-cell tumors based on rodent studies in which GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma [3][4]. These drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The FDA states explicitly that human relevance of the rodent data is unknown, and a post-marketing epidemiological study has not established a causal link in humans [3].

Clinicians at HealthRX follow a pre-treatment screen that asks about personal and family thyroid cancer history, specifically medullary thyroid carcinoma, before approving any GLP-1 prescription.

Hypoglycemia

Hypoglycemia risk is low in patients taking GLP-1 agonists as monotherapy because these drugs stimulate insulin secretion in a glucose-dependent manner. They do not cause insulin release when blood glucose is normal or low. Risk becomes clinically relevant only when GLP-1 agents are combined with insulin or sulfonylureas. In STEP-2 (Davies et al., Lancet 2021, N=1,210), which enrolled patients with type 2 diabetes, symptomatic hypoglycemia occurred in 5.6% of the semaglutide 2.4 mg arm, with most events occurring in patients who also used insulin [17].

How Long Do GLP-1 Side Effects Last?

Side effect duration varies by symptom type. Nausea typically peaks during the first 4 weeks at each new dose and resolves in the majority of patients by week 12 of continuous treatment [1][3]. In STEP-5, which followed patients for 104 weeks, GI adverse events were substantially less frequent in the second year than the first [13], confirming that tolerance develops.

Constipation follows a different pattern. It can persist throughout treatment because the underlying mechanism (slowed colonic transit) remains active as long as the drug is on board [8]. Ongoing fiber and fluid strategies are needed for the duration of therapy, not just the titration phase.

Sulfur burps generally improve once gastric emptying adaptation occurs, usually within 8 to 12 weeks, but dietary triggers can restart them at any point during treatment.

Gallbladder risk does not diminish with time. It tracks with cumulative weight loss and may actually increase modestly beyond 6 months as the degree of weight loss grows [1][13][14]. Patients with any prior biliary history warrant periodic clinical reassessment throughout the first year.

When to Call Your Doctor or Go to the Emergency Room

Most GLP-1 side effects can be managed outpatient with dietary adjustments and titration modifications. Several symptom patterns require immediate evaluation [3][4]:

Call your prescriber same day:

• Nausea or vomiting that prevents keeping any fluids down for more than 12 hours
• No bowel movement for 5 or more consecutive days with abdominal bloating
• New or worsening heartburn unresponsive to antacids
• Resting heart rate persistently above 100 bpm (tachycardia is a labeled adverse event for tirzepatide at higher doses) [4]

Go to the emergency room immediately:

• Severe upper-abdominal or mid-epigastric pain lasting more than 2 hours, especially if radiating to the back (possible pancreatitis)
• Right-upper-quadrant pain with fever and/or jaundice (possible cholecystitis)
• Signs of dehydration: dizziness on standing, dark urine, no urination for 8 or more hours
• A neck lump or persistent hoarseness (possible thyroid concern, though rare)

The Wegovy prescribing information recommends monitoring renal function in patients who experience significant GI events leading to volume depletion [3], and the same guidance appears in the Zepbound label [4].

Drug-Specific Side-Effect Differences: Semaglutide vs. Tirzepatide

Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. That dual mechanism changes the side-effect signature modestly.

In SURMOUNT-1 versus STEP-1 direct comparison (acknowledging these are separate trials with different populations), nausea rates were lower with tirzepatide 15 mg (39%) than semaglutide 2.4 mg (44.2%) despite tirzepatide producing greater mean weight loss (20.9% vs. 14.9%) [1][2]. This may reflect the GIP component attenuating GLP-1-driven GI effects, a hypothesis supported by preclinical data showing GIP receptor activation can modulate GLP-1 receptor sensitivity in the gut [18].

Heart rate increase is more prominent with tirzepatide. SURMOUNT-1 showed a mean increase of 2 to 4 beats per minute from baseline on the 15 mg dose [2]. This is a labeled finding in the Zepbound prescribing information and is relevant for patients with pre-existing arrhythmias or tachycardia [4].

Injection site reactions (redness, bruising, nodule formation) occur with both drugs at similar low rates, under 10% in trial populations [1][2]. Rotating injection sites across the abdomen, thigh, and upper arm reduces local reactions.

In STEP-8 (N=338, JAMA 2022), semaglutide 2.4 mg weekly produced 15.8% weight loss versus 6.4% for once-daily liraglutide 3.0 mg at 68 weeks, with semaglutide showing a lower rate of nausea (29% vs. 37%) and fewer discontinuations [7]. Liraglutide is now rarely used for obesity because of this inferior tolerability-to-efficacy ratio.